Phase 2 Start
COLL: Phase2_Start: Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial
April 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- April 1, 2027
- Company
- COLLEGIUM PHARMACEUTICAL, INC (COLL)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start